Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume Control Clear all
Completed Phase 1Phase 2 Interventional Results available

Aerosol Inhalation Treatment for Dyspnea - Patients

NCT02524054
View directory record Official record
Conditions
Dyspnea
Interventions
Furosemide, Aerosolized saline
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 29, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Hypoxia Pathways for Early Recovery After Spinal Cord Injury

NCT07002437
View directory record Official record
Conditions
Spinal Cord Injuries (SCI)
Interventions
Augmented Acute Intermittent Hypoxia (aAIH), Acute Intermittent Hypercapnic-Hypoxia (AIHH), Sham AIH
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Hydrocortisone for Term Hypotension

NCT01954056
View directory record Official record
Conditions
Infant, Newborn, Diseases, Cardiovascular Insufficiency
Interventions
Hydrocortisone, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
34 Weeks and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 29, 2026, 9:22 PM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705
View directory record Official record
Conditions
Healthy or Stable Underlying Chronic Medical Condition
Interventions
Q/LAIV-BFS (MEDI8662), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Sacramento, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

NCT05188261
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

NCT00323037
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol controlled release, carvedilol immediate release
Drug
Lead sponsor
CTI-1, LLC
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
75
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03960957
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA, Placebo
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Redondo Beach, California • San Diego, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 29, 2026, 9:22 PM EDT
Completed No phase listed Observational Results available

Effect of Alveolar Minute Ventilation on Respiratory Gas Heat Content

NCT01943227
View directory record Official record
Conditions
Ventilation Perfusion Mismatch
Interventions
controlled positive pressure ventilation 9ml/kg tidal volume, controlled positive pressure ventilation 6ml/kg tidal volume
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Coronary Artery Disease in Patients With Friedreich's Ataxia

NCT04649866
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
plethysmography
Diagnostic Test
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 29, 2026, 9:22 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Effect of Povidone Iodine on the Dental Implant Internal Surface Microbiome

NCT07899983
View directory record Official record
Conditions
Dental Implant
Interventions
Povidone-Iodine
Drug
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 9:22 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Phase 2B Study Assessing Pain Relief After Replacement of the Knee

NCT06799845
View directory record Official record
Conditions
Total Knee Arthroplasty (Postoperative Pain)
Interventions
ATX101, bupivacaine hydrochloride, saline placebo
Drug
Lead sponsor
Allay Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Little Rock, Arkansas • Tamarac, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 9:22 PM EDT
Not listed Phase 1Phase 2 Interventional

Siltuximab in Schizophrenia

NCT02796859
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Siltuximab, normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 29, 2026, 9:22 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

NCT03656510
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 3 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Madera, California • Ventura, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Results available

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

NCT01393782
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

NCT00816023
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
ecallantide, placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Not applicable Interventional

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

NCT01812447
View directory record Official record
Conditions
Emphysema
Interventions
Spiration Valve System, Medical Management
Device · Other
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
32
States / cities
Fort Smith, Arkansas • Riverside, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

NCT04849559
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 29, 2026, 9:22 PM EDT
Completed Not applicable Interventional Results available

Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid

NCT02051686
View directory record Official record
Conditions
Acetabulum Fractures
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 29, 2026, 9:22 PM EDT